Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
300 participants
OBSERVATIONAL
2025-08-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Entia Liberty: Accuracy and Precision
NCT05025124
Entia Liberty: Home Study
NCT05462288
Entia Liberty: Capillary Validation
NCT05025111
Capillary Blood Accuracy
NCT06544070
Hydration Factor Study for the Stayhealthy BC3
NCT01209936
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy volunteers
Liberty Analyzer WBC System
Participants will donate capillary samples to be analysed by the Liberty Analyzer System WBC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Liberty Analyzer WBC System
Participants will donate capillary samples to be analysed by the Liberty Analyzer System WBC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to provide written informed consent
Exclusion Criteria
* Undergone tattooing or body piercing within the 7 days prior to the study visit
* Undergone vaccination within the 7 days prior to the study visit
* Episode of upper respiratory infection within the 30 days prior to the study visit
* Use of oral corticosteroid medications within the 30 days prior to the study visit
* Undergone surgery within the 90 days prior to the study visit
* Been hospitalised within the 90 days prior to the study visit
* Donated blood or plasma within the 90 days prior to the study visit
* Pregnant at the time of the study visit
* Breastfeeding at the time of the study visit
* Current diagnosis of anemia (including iron deficiency anemia, vitamin deficiency anemia, aplastic anemia and/or hemolytic anemia)
* Current diagnosis of high blood pressure
* Current diagnosis of diabetes mellitus
* History or current diagnosis of chronic kidney disease or end-stage renal disease
* History or current diagnosis of cancer
* History or current diagnosis of cardiovascular disease
* History or current use of radiotherapy of the chest or abdomen
* History or current diagnosis of the following conditions known to affect the CBC differential count:
* Immune Thrombocytopenic Purpura (ITP)
* Systemic Lupus Erythematosus (SLE)
* Rheumatoid Arthritis (RA)
* Antiphospholipid Syndrome (APS)
* Sjogren's Syndrome
* Tuberculosis (TB)
* HIV
* Hepatitis B/C
* G6PD Deficiency
* Sickle Cell Disease/Trait
* Inflammatory Bowel Disease (IBD)
* Eptein Barr virus
* CMV Cytomegalovirus
* Myelodysplastic Syndromes (MDS) / CMML
* Asplenia
Participants who meet the following criteria will be excluded a posteriori:
* Hemoglobin, hematocrit, red cell and/or total white blood cell count obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site.
* Iron, ferritin, transferrin, total Iron Binding Capacity (TIBC) and/or transferrin saturation results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site.
* Alanine aminotransferase (ALT), aspartate aminotransferase ( AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, conjugated bilirubin, albumin and/or total protein results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site.
* Creatinine, estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), sodium, potassium, chloride and/or bicarbonate results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site.
* C-reactive protein (CRP) results obtained by standard laboratory analysis of the participant's venous blood sample, that fall outside of the applicable reference interval in use at the study site.
* Self-report to be taking medication(s) that are subsequently identified as interfering substances for the Liberty Analyzer WBC System
21 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Entia Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTM-PRO-00174
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.